- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00827632
Obesity, Oral Contraception, and Ovarian Suppression (20/30)
Oral Contraception and Ovarian Suppression in Women With Different Weights
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Actual)
Phase
- Phase 4
Contacts and Locations
Study Locations
-
-
New York
-
New York, New York, United States, 10032
- Columbia University Medical Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Aged 18-35
- Body Mass Index (BMI) 19-24.9 or 30-39.9 kg/m^2
- Willing to take birth control pills for 3-4 months
- Recent spontaneous pregnancy or cyclic menses
Exclusion Criteria:
- Contraindications to hormonal contraceptives
- Oophorectomy/Polycystic ovary syndrome (PCOS)
- Taken oral contraceptives to regulate menses recently
- Weight reduction surgery
- Used Depo-Provera within the last 12 months
- Pregnant or currently breastfeeding
- Desiring pregnancy within the next 4 months
- Unable to make study visit commitment
- Previous participation in this study
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Normal Weight group
Participants with a BMI of 19-24.9
kg/m^2
|
Participants are randomized to either Portia (levonorgestrel/ethinyl estradiol tablets, United States Pharmacopeia (USP)0.15 mg/0.03 mg or Lessina (levonorgestrel/ethinyl estradiol tablets, USP 0.1 mg/0.02 mg) for 3 months use. Dose formula contains 20 ug of ethinyl estradiol (EE) and 100 ug of levonorgestrel (LN) per tablet.
Other Names:
Participants are randomized to either Portia (levonorgestrel/ethinyl estradiol tablets, United States Pharmacopeia (USP)0.15 mg/0.03 mg or Lessina (levonorgestrel/ethinyl estradiol tablets, USP 0.1 mg/0.02 mg) for 3 months use. Dose formula contains 30 ug of ethinyl estradiol (EE) and 150 ug of levonorgestrel (LN) per tablet.
Other Names:
|
Active Comparator: Obese group
Participants with a BMI of 30-39.9
kg/m^2
|
Participants are randomized to either Portia (levonorgestrel/ethinyl estradiol tablets, United States Pharmacopeia (USP)0.15 mg/0.03 mg or Lessina (levonorgestrel/ethinyl estradiol tablets, USP 0.1 mg/0.02 mg) for 3 months use. Dose formula contains 20 ug of ethinyl estradiol (EE) and 100 ug of levonorgestrel (LN) per tablet.
Other Names:
Participants are randomized to either Portia (levonorgestrel/ethinyl estradiol tablets, United States Pharmacopeia (USP)0.15 mg/0.03 mg or Lessina (levonorgestrel/ethinyl estradiol tablets, USP 0.1 mg/0.02 mg) for 3 months use. Dose formula contains 30 ug of ethinyl estradiol (EE) and 150 ug of levonorgestrel (LN) per tablet.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Risk of Oral Contraceptive (OC) Failure Due to Less Contraceptive-mediated Ovarian Suppression.
Time Frame: Up to 8 biweekly visits from start of OCP therapy
|
Perpendicular diameter, ethinyl estradiol, and progesterone values were used to create Hoogland Scores. Hoogland Scores were used to assess ovarian suppression during OC use. The Hoogland Score comprises 6 grades (Because of small numbers, grades 5 and 6 were combined):
Each participant received a score from 1-6 to indicate the level of ovarian suppression; total number of participants were tallied for each Hoogland score. |
Up to 8 biweekly visits from start of OCP therapy
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Lipid or Carbohydrate Metabolism in Obese Versus Normal Weight Oral Contraceptive (OC) Users at Baseline and Exit Visit (12-16 Weeks OC Exposure).
Time Frame: Screening (baseline) and follow-up 1 (exit)
|
Screening (baseline) and follow-up 1 (exit)
|
Pharmacokinetics of 15 Obese Weight and 15 Normal Weight Women on Combined Oral Contraceptives.
Time Frame: 24 hours during week 3 of follow-up cycle
|
24 hours during week 3 of follow-up cycle
|
Collaborators and Investigators
Publications and helpful links
General Publications
- Mayeda ER, Torgal AH, Westhoff CL. Weight and body composition changes during oral contraceptive use in obese and normal weight women. J Womens Health (Larchmt). 2014 Jan;23(1):38-43. doi: 10.1089/jwh.2012.4241. Epub 2013 Oct 24.
- Westhoff CL, Torgal AH, Mayeda ER, Stanczyk FZ, Lerner JP, Benn EKT, Paik M. Ovarian suppression in normal-weight and obese women during oral contraceptive use: a randomized controlled trial. Obstet Gynecol. 2010 Aug;116(2 Pt 1):275-283. doi: 10.1097/AOG.0b013e3181e79440.
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- AAAB4823
- R01HD045786 (U.S. NIH Grant/Contract)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Ovarian Suppression
-
Alaa Mazy MazyCompletedImmune SuppressionEgypt
-
Dana-Farber Cancer InstituteHoward Cox Fund for Women Assistant ProfessorsCompletedSexual Function Disturbances | Breast Cancer Survivors | Ovarian Suppression TreatmentUnited States
-
TheramexCompletedSuppression of Ovulation
-
Assiut UniversityUnknownImmune System SuppressionEgypt
-
Health DecisionsEunice Kennedy Shriver National Institute of Child Health and Human Development... and other collaboratorsCompletedSuppression of OvulationUnited States
-
Health DecisionsEunice Kennedy Shriver National Institute of Child Health and Human Development...Completed
-
Oslo University HospitalActive, not recruitingKidney Transplant; Complications | Immune SuppressionNorway
-
Agile TherapeuticsCompletedOvulation SuppressionUnited States
-
Heidelberg UniversityCompletedAnesthesia Complication | Immune Suppression
-
University of ChileNot yet recruitingAnesthesia, Intravenous | Electroencephalography | Burst SuppressionChile
Clinical Trials on Low dose formulation
-
GlaxoSmithKlineActive, not recruitingHepatitis B, ChronicTaiwan, Belgium, Thailand, Germany, Spain, Hong Kong, United Kingdom, France, Poland
-
Themis Bioscience GmbHCompletedChikungunya Virus InfectionUnited Kingdom
-
GlaxoSmithKlineCompletedRespiratory Syncytial Virus InfectionsTaiwan, Spain, United States, Italy, Canada, Panama, Mexico, Poland
-
GlaxoSmithKlineTerminated
-
Sanofi Pasteur, a Sanofi CompanyCompletedPneumonia | Pneumococcal Infections | Streptococcus Pneumoniae InfectionsBangladesh
-
PfizerActive, not recruiting
-
LEO PharmaCompletedActinic KeratosisCanada, United States
-
AbbVieCompleted
-
GlaxoSmithKlineCompleted
-
Goldman, Butterwick, Fitzpatrick and GroffL'OrealCompleted